GSGTF
GenSight Biologics S.A.·Healthcare
0.19
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.1952W H: $0.48
GSGTF NEWS
businesswire.com
3d ago
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and the revenues from its Named Patient Early Access Program as of March 31, 2026. Cash position as of March 31, 2026 GenSight Biologics' cash and cash equivalents totaled €3.2 million.
businesswire.com
Apr 3
GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today confirmed that its definitive annual results for the fiscal year ended 2025 are in line with the estimated figures published on March 27, 2026. Confirmation of Results The definitive consolidated and individual.
businesswire.com
Mar 27
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported estimated full-year consolidated financial results for 2025,1 as reviewed by the Audit Committee and the Board of Directors on March 25, 2026. The Board of Directors will approve the final accounts on A.
businesswire.com
Mar 20
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
PARIS--(BUSINESS WIRE)--Regulatory News: The 15-20 National Hospital (l'Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the first patients have been treated in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®.1 The REVISE.
businesswire.com
Mar 9
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided updates on the GS010/LUMEVOQ® early access programs currently underway and the ongoing dose-ranging study REVISE. GS010/LUMEVOQ® is the Company's candidate gene therapy in clinical development as a trea.
businesswire.com
Feb 18
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the strategic expansion of its Regulatory Affairs & Quality department with two senior appointments following recent regulatory milestones. The company named.
